Individual Patient Expanded Access-Glembatumumab Vedotin
NCT03067935 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2018-05-21
Summary
Celldex endeavors to make investigational products available to patients with life-threatening diseases who have exhausted other treatment options and where there is a reasonable expectation of benefit over risk. Requests for expanded access to glembatumumab vedotin in patients with gpNMB expressing triple negative breast cancer will be considered.
Conditions
- Metastatic gpNMB Expressing Triple Negative Breast Cancer
Interventions
- DRUG
-
glembatumumab vedotin
Sponsors & Collaborators
-
Celldex Therapeutics
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
NCT01881230 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
NCT06178159 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer
NCT01201265 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer
NCT06229067 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
NCT03330847 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
NCT03362060 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis
NCT06137651 ·Status: WITHDRAWN ·Phase: PHASE1
-
Gemcitabine in Treating Women With Metastatic Breast Cancer Previously Treated With Doxorubicin and Paclitaxel
NCT00003540 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
NCT06966453 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer
NCT00193063 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
NCT01156753 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
NCT02032277 ·Status: COMPLETED ·Phase: PHASE3
-
Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer
NCT01167192 ·Status: TERMINATED ·Phase: PHASE2
-
Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer
NCT04739670 ·Status: RECRUITING ·Phase: PHASE2
-
Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
NCT06227117 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined with VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients with Advanced HER2-Negative Breast Cancer with Brain Metastasis
NCT06839560 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Triple Negative Breast Cancer Trial
NCT00532727 ·Status: UNKNOWN ·Phase: PHASE3
-
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
NCT04647916 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
NCT07017673 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)
NCT01953536 ·Status: WITHDRAWN ·Phase: PHASE2
-
Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer
NCT03206203 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors
NCT00998036 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
NCT02536339 ·Status: COMPLETED ·Phase: PHASE2
-
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
NCT00483223 ·Status: COMPLETED ·Phase: PHASE2
-
RX-5902 Treatment of Subjects With Triple Negative Breast Cancer
NCT02003092 ·Status: TERMINATED ·Phase: PHASE1/PHASE2